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Introduction: Arteriovenous fistula (AVF) nonmaturation increases reliance of hemodialysis patients on grafts and
catheters, exposing them to associated high complication risks. This systematic review assessed the success rates and
complications of therapeutic interventions in arm hemodialysis AVFs experiencing nonmaturation. It also compared the
efficacy of preoperative clinical factors (eg, age, gender, race), and preoperatively and postoperatively acquired hemody-
namic parameters (eg, arterial diameter or blood flow through the AVF) at stratifying risk of nonmaturation.
Methods: Two independent researchers used a systematic strategy to search literature databases and extract data from
articles judged relevant and valid. The evidence base for this review comprised 33 articles, 12 about treatment, and 21
concerning risk stratification. A meta-analysis was performed to calculate summary measures for nonmaturation
treatment success and risk stratification efficacy (eg, excess risk and relative risk) of preoperative clinical, preoperative
hemodynamic, and postoperative hemodynamic risk factors.
Results: The success rate of early endovascular or surgical treatment, defined as the possibility of achieving adequate
hemodialysis, averaged 86%, with 1-year primary patencies of 51%, 1-year secondary patencies of 76%, and complication
rates of 9.3%, with 5.5% minor complications. Overall, patients with preoperative clinical risk factors had excess
nonmaturation risks of 21% (95% confidence interval [CI], 11%-30%) and a relative risk of 1.7 (95%CI, 1.3-2.1). Patients
with preoperative hemodynamic risk factors had average estimated excess risks of 24% (95% CI, 15%-33%) and a relative
risk of 1.7 (95% CI, 1.4-2.0). Patients with hemodynamic risk factors present shortly after operation had excess
nonmaturation risks of 50% (95% CI, 42%-58%) and a relative risk of 4.3 (95% CI, 3.4-5.5).
Conclusions: Patients can be treated effectively for AVF nonmaturation early on, and it is possible to identify those
patients at risk of nonmaturation most effectively with an early postoperative assessment of hemodynamic risk factors.
Additional research is needed that concentrates on adopting the strategy of early treatment of patients with postoperative
risk factors. ( J Vasc Surg 2009;49:1325-36.)Current treatment guidelines in the United States of
America and in Europe have identified the autogenous
arteriovenous fistula (AVF) as the preferred type of vascular
access for chronic hemodialysis patients.1,2 AVFs have bet-
ter patency rates,3 fewer complications,4 and lower health
care costs5 than arteriovenous grafts (AVGs) and catheters.
More important, the use of AVGs and catheters is associ-
ated with increased mortality.6,7
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doi:10.1016/j.jvs.2008.11.059Most AVFs require a maturation period of 4 to 6 weeks
before they can be used for hemodialysis; however, substantial
numbers ofAVFsdonotmature to a condition able to provide
adequate dialysis. These AVFs, which experience nonmatura-
tion, are left to mature longer—but often without success—
and are frequently eventually abandoned altogether. We have
recently shown that nonmaturation, defined as insufficient
AVF flow to maintain hemodialysis after a maturation period
of 6 weeks, occurred in 19% of patients.8 These patients must
then rely more extensively on grafts and catheters for interim
dialysis, which exposes them to increased risks.
This problem could hypothetically be reduced when
those patients at high risk of nonmaturation could be
identified before or early within the maturation period and
treated with surgical or endovascular methods 4 to 6
weeks postoperatively to induce maturation. This would
minimize additional maturation time and prevent pro-
longed reliance on alternative vascular accesses.
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edge of which AVFs are at risk of nonmaturation would be
required before 4 weeks. Therefore, a tool for objective risk
stratification that could be used before or shortly after the
AVF surgery would be useful. Such tools have been pro-
posed previously. Overall, risk stratification can be per-
formed using clinical risk factors such as age, gender, race,
or comorbidity,9 or using anatomic and hemodynamic
parameters of the native vasculature imaged preoperatively,
such as cephalic vein and radial artery diameter or blood
flow.10 Alternatively, nonmaturation risk can be stratified
from hemodynamic information such as blood flow or flow
velocity through newly created AVFs imaged early postop-
eratively.11
Currently, it remains unclear whether early treatment
of nonmaturation is safe and effective. It is also unknown
which method of risk stratification has highest efficacy.
Therefore, our aims were:
1. To systematically review and meta-analyze the reported
success rates and complications of interventions in non-
maturing AVFs.
2. To identify the best technique for nonmaturation risk
stratification by quantitatively comparing reported effi-
cacies of preoperative clinical and hemodynamic, and
postoperative hemodynamic risk stratification methods.
METHODS
Bibliographic database search. A search syntax con-
sisting of synonyms of the following Boolean combination
of terms was constructed to conduct a computer-aided
search of the MEDLINE, EMBASE, and Cochrane librar-
ies, from the inception of these databases until February 12,
2008: “arteriovenous fistulas” and “hemodialysis patients”
and (“computed tomography” or “magnetic resonance
imaging” or “ultrasound” or “hemodynamics” or “risk
factors”) and “AVF outcome.” A hand-search of bibliog-
raphies of articles that remained after study selection was
also performed.
Publication selection. Inclusion criteria were formu-
lated a priori. Included were articles presenting original
data obtained from human hemodialysis patients with pri-
mary upper extremity AVFs that were either treated for
nonmaturation or in which noninvasively acquired objec-
tive risk factors for nonmaturation were assessed, and in
whom outcomes were evaluated after at least 4 weeks
post-AVF creation. Only articles written in English, French,
German, or Dutch were included.
Exclusion criteria were formulated a priori. Excluded
were articles that included 15 patients (6 studies), or
samples in which nonmaturation did not occur at all (3
studies), or articles that had a too-short follow-up period of
4 weeks (3 studies). In addition, risk stratification articles
were discarded that did not report values of risk factors for
matured and nonmatured AVF groups separately (21 stud-
ies) because their data could not be used for calculation of
summary measures for risk stratification efficacy. Also ex-
cluded were articles about treatment of primary failingAVFs that failed to report outcomes (4 studies). Two
researchers (E. H. J. V. and A. K. J.) performed inclusion
and exclusion of articles independently. Disagreements
were resolved on consensus.
After selection, articles were categorized into treatment
and risk stratification categories. Subsequently, risk stratifi-
cation studies were divided into three categories: preoper-
ative clinical risk stratification studies (preclinical), preop-
erative hemodynamic risk stratification studies (pre-HRS),
and postoperative hemodynamic risk stratification studies
(post-HRS).
Next, selected studies were critically appraised and sub-
jected to systematic data extraction, pooling, and calcula-
tions of summary measures.
Critical appraisal of selected studies. The method-
ologic quality of selected studies was assessed in terms of
possible bias (internal validity) and lack of generalizability
(external validity). A scoring system adapted from check-
lists provided by the Dutch Cochrane Collaboration12 was
used for this purpose. Table I lists items that were scored. A
1 was assigned if an article used adequate methods. A 0 was
assigned for inadequate methods, or for insufficient infor-
mation. Finally, an overall quality score was expressed as a
percentage of the maximum score (treatment maximum
score  8, risk stratification maximum score  9). We
arbitrarily labelled studies scoring 90% to 100%, 60% to
100%, and 60% as methodologically “good,” “fair,” and
“poor,” respectively.
Data extraction and summary measure definitions.
The goal of data extraction was to gather data from the
body of included studies to compute summarymeasures for
nonmaturation treatment and risk stratification efficacy.
Data were extracted by one researcher (E. H. J. V.) and
verified by another (A. K. J). For treatment studies, data
about treatment success and 1-year primary and secondary
patency were extracted from each individual study.
Summary measures of these individual parameters were
obtained by multiplying them with their corresponding
study population size, adding them, and subsequently
computing the weighted average. Furthermore, for each
risk factor reported in the included risk stratification stud-
ies, the following summary measures for risk stratification
efficacy were calculated:
● Excess risk: The difference between the absolute non-
maturation risk of patients considered at risk (ie, pa-
tients with risk factors) and considered not at risk (ie,
patients without risk factors). A measure of 0% means
no risk is conferred by the risk factor.
● Relative risk: The nonmaturation risk of a patient at
risk divided by the nonmaturation risk of a patient not
at risk. A measure of 1.0 means no risk is conferred.
These measures were used to quantify the efficacy of
risk stratification on a patient level.
● Sensitivity and specificity: These were used to assess
the discriminative ability of risk stratification tools as if
they were a diagnostic test.
lar cri
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from included studies in two  two tables and calculating
average point estimates according to standard formulas.13
Definitions. The definition of nonmaturation in this
review is an AVF that was left to mature for a minimum of
4 weeks up to a maximum of 24 weeks, within which it was
evaluated and found to be unsuitable for adequate hemo-
dialysis. Note nonmaturation was defined broadly to apply
to all included articles. The 1-year primary patency was
defined as the number of functioning AVFs at 1 year after
AVF creation in which no treatments were performed after
an initial successful treatment for nonmaturation, divided
by the total number of AVF created. The 1-year secondary
patency was defined as the number of functioning AVF at 1
year after creation, including all AVF which did receive
treatment after initial salvage, divided by the total number
created.
RESULTS AND QUALITY OF STUDIES
Search results. Our search identified 1794 articles.
After discarding duplicate articles, 1449 studies remained.
Table I. Criteria for critical appraisal of study quality
No.a Validity
Internal validity
1 Prospective study Data were prospectivel
2 Minimum data loss 10% of population w
had missing outcom
3 Objective determinant
definition
Risk stratification studi
hemodynamic risk st
at what anatomic loc
Treatment studies: Art
performed treatment
4 Objective outcome definition Risk stratification studi
achieving minimum
number or period of
Treatment studies: Ma
successful dialysis for
number of successfu
5 Independence of risk factor The studied risk factor
other possible risk fa
independence from o
6 Nonintervention control
group
Control group was inc
7 Minimum of confounding
bias
When control and trea
post hoc statistical ad
differences in confou
External validity
8 Minimum of population bias An included population
9 Minimum of patient filtering
bias
Inclusion criteria descr
10 Minimum of observer
variability bias
Interpreters of risk fact
observed hemodynam
10%.
11 Validation of risk factor Risk bestowed by extra
bootstrapping) or ex
AVF, Arteriovenous fistula; HRS, hemodynamic risk stratification.
aNumbers of criteria corresponding to numbers in Table II.
bCondition in which case a “1” was awarded (Table II).
c“Treatment” designates only treatment studies were assessed on that particu
criterion. “Both” means both treatment and risk estimation studies were asThese were assessed on the basis of inclusion criteria and 71studies were included. Of these, 37 were excluded based on
previously described criteria, and 33 studies were selected
for final inclusion. These were 12 treatment papers14-25 and
eight preclinical articles,9,26-32 of which seven more were
discarded after critical appraisal. So, one preclinical study
finally remained (this is explained further subsequently).
Seven pre-HRS studies,10,33-38 six post-HRS studies,11,39-43
and one study that evaluated both preoperative and postop-
erative hemodynamic risk factors44 were selected for final
inclusion as well. Quality scores of these studies are reported
in Table II.
For each study, sample sizes, baseline characteristics (ie,
potential confounders), nonmaturation prevalence, defini-
tions of nonmaturation, and treatment successes, if appli-
cable, are compiled in Table III. Results of treatment
studies are given in Table IV. Results of risk stratification
studies are provided in Table V.
Efficacy and safety of early treatment of nonmatur-
ing AVFs. The selected articles comprised 745 patients
who were treated for nonmaturation. The average postop-
erative age of the AVF at the time of treatment was 3.2
Positive score whenb Applied toc
ered. Both
t to follow-up, had withdrawn from the study, or
.
Both
ticle gives definitions of risk factors. For
, it describes at what time pre-op or post-op, and
hemodynamic factors were measured.
Risk
escribes methods of all different procedures Treatment
onmaturation was defined in terms of (1) not
nt vein diameter or flow or (2) not achieving
ssful dialysis sessions, or both.
Risk
on was defined as (1) AVF able to sustain
ast a minimum period of time or (2) minimum
sis sessions.
Treatment
s an independent predictor of outcome apart from
(eg, regression modelling was performed to prove
factors).
Risk
in the study. Treatment
t group were assigned (nonrandomly), matching or
ent was performed to prevent systematic
s between groups.
Treatment
described as a consecutive or random sample. Both
age and gender reported. Both
escribed. For HRS studies, if multiple raters
sk factors, then interrater variability should be
Risk
risk factor(s) was validated internally (eg,
lly (independent sample).
Risk
terion. “Risk” designates only risk stratification studies were assessed on that
on the criterion in question.y gath
as los
e data
es: Ar
udies
ation
icle d
.
es: N
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turati
at le
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(s) wa
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ibed;
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ternamonths (range, 13 days-2 years). Table IV lists relative
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ferent treatment techniques used to treat nonmaturation,
and treatment results.
Singh et al25 (2007) was the only study with a control
group. Therefore, only this study was able to quantify
treatment effect: a 47% (95% confidence interval [CI],
25%-70%) increase in maturation chance occurred when
primary failing AVFs were treated early.25
Overall, 85.5% of treated patients (range, 74%-98%)
were able to use their AVF at least once for hemodialysis
after treatment. Six articles reported an average 1-year
primary patency of 51% (range, 28%-68%),14,15,17-20 and
seven reported an average 1-year secondary patency of 76%
Table II. Methodologic quality of selected studies
First author
Year
Cr
Internal validi
Treatment 1 2 3 4 5
Clark19 2007 0 1 1 1 . . .
McLafferty24 2007 0 1 1 1 . . .
Singh25 2007 0 0 0 0 . . .
Song15 2006 0 1 1 1 . . .
Falk16 2006 0 0 0 1 . . .
Asif23 2006 1 1 1 1 . . .
Shin17 2005 0 0 1 1 . . .
Nassar18 2005 1 1 1 1 . . .
Beathard20 2003 1 1 1 1 . . .
Faiyaz22 2002 1 1 1 1 . . .
Turmel-Rodrigues14 2001 0 1 1 0 . . .
Beathard21 1999 1 1 1 1 . . .
Mean treatment
Risk stratification
Pre-clinical
Lok9 2006 1 1 1 1 1
Pre-HRS
Korten33 2007 1 1 0 0 0
Parmar35 2007 1 1 0 0 0
Van der Linden34 2006 1 1 1 1 0
Lockhart36 2004 1 0 0 1 0
Tordoir37 2003 1 1 0 1 0
Brimble38 2002 0 1 0 1 1
Mendes10 2002 1 1 0 0 0
Mean pre-HRS
Post-HRS
Robbin41 2002 0 0 0 1 0
Chiang43 2001 1 1 1 0 0
Kim11 2001 1 1 1 0 0
Won42 2000 1 1 1 1 0
Johnson40 1998 1 0 1 0 1
Elfstrom39 1981 1 1 1 0 0
Mean post-HRS
Pre- and post-HRS
Wong44 1996 1 1 1 1 0
Mean risk stratification
HRS, Hemodynamic risk stratification; post-HRS, postoperative hemodyna
studies.
aSee Table I for criteria of validity.
bSum of scores for all criteria. Treatment studies could score 8 maximally, a
cPercentage of maximum achievable score per study.(range, 72%-95%).14,15,17-19,21,23Eight articles specified complications for 508 pa-
tients.14-20,22 Overall, complications occurred in 47 pa-
tients (9.3%). Hematomas at puncture sites or small post-
angioplastic extravasations without clinical sequelae were
reported in 28 patients (5.5%). Venous ruptures occurred
in 11 patients (2.2%) during percutaneous transluminal
angioplasty, and five (1.0%) experienced steal syndrome. A
pseudoaneurysm developed in one patient, bacteremia de-
veloped in another, and one patient lost his AVF after a vein
rupture.
The mean overall quality score for treatment studies
was 55% (range, 25%-75%), which was considered poor.
The most profound design weakness of treatment studies
of validitya
Scoreb
Quality,c
%
External validity
6 7 8 9 10 11 Max 8/9
0 1 1 . . . . . . 5 63
0 0 1 . . . . . . 4 50
0 1 1 . . . . . . 3 38
0 1 0 . . . . . . 4 50
0 1 0 . . . . . . 2 25
0 1 1 . . . . . . 6 75
0 0 1 . . . . . . 3 38
0 1 1 . . . . . . 6 75
0 1 1 . . . . . . 6 75
0 1 1 . . . . . . 6 75
0 0 1 . . . . . . 3 38
0 1 0 . . . . . . 5 63
55
. . . . . 1 1 1 1 9 100
. . . . . 1 1 0 0 4 44
. . . . . 1 1 0 0 4 44
. . . . . 1 1 0 0 6 67
. . . . . 1 1 0 0 4 44
. . . . . 1 1 0 0 5 56
. . . . . 1 1 0 0 5 56
. . . . . 1 1 0 0 4 44
51
. . . . . 0 1 0 0 2 22
. . . . . 1 0 1 0 5 56
. . . . . 1 1 1 0 6 67
. . . . . 1 1 0 0 6 67
. . . . . 1 1 0 0 5 56
. . . . . 0 1 0 0 4 44
52
. . . . . 1 1 0 0 6 67
56
isk stratification studies; pre-clinical, preoperative clinical risk stratification
modynamic risk stratification articles could score 9.iteria
ty
0
0
1
0
0
0
0
0
0
0
0
0
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
mic rwas the lack of control groups. The presence of hetero-
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tics (Table III) and the lack of adjustment for confound-
ing bias (Table II) limited the reliability of summary
measures.
Efficacy of preoperative clinical risk stratification.
Of all included preclinical studies, the 2006 study by Lok et
al9 had an overall quality score of 100% (Table II), whereas
the other studies scored an average of 67% (data not
shown). Moreover, Lok et al9 had by far the largest sample
size and performed superior validation of identified risk
factors. Pooling the data from Lok et al9 with data from the
other seven relatively poor-quality studies would lead to
more bias in our summary measure, instead of less. There-
fore, only the data from Lok et al9 were used to compute
the summary measure for the efficacy of preoperative clin-
ical risk stratification.
Lok et al9 defined a clinical prediction rule that estimates
risk by scoring the four clinical characteristics of age, race, and
a history of peripheral vascular disease or coronary artery
disease. This score, with amaximumof 10.5, defined four risk
categories of low risk (score2), moderate risk (2 to 3), high
risk (3 to 7) and very high risk (7), with nonmaturation risks
of 24%, 34%, 50%, and 69%, respectively.
The clinical utility of having more than two risk cate-
gories is dubious when the objective is to decide whether to
treat or not to treat a patient for nonmaturation. Therefore,
to calculate risk stratification measures here, we used a
cutoff score of 3. Patients scoring 3 were considered not
at risk, whereas patients scoring above the cutoff were
considered at risk. Patients at risk had 51% risk of nonmatu-
ration, a significant excess risk (ER) of 21% (95% CI,
11%-30%), and a relative risk (RR) of 1.7 (95% CI, 1.3-
2.1). On test level, the classification of future AVFs as
maturing or nonmaturing had an estimated sensitivity of
0.53 (95% CI, 0.45-0.60) and specificity of 0.68 (95% CI,
0.62-0.73).9
Efficacy of preoperative hemodynamic risk strati-
fication. Most pre-HRS articles evaluated multiple risk
factors but allowed quantification of risks for a limited
number because of incomplete data reporting. All pre-HRS
studies were conducted in cohorts containing just radioce-
phalic AVFs; therefore, pre-HRS results apply to radioce-
phalic AVFs only.
Small radial artery diameters with cutoff values of
2.0,33,37 1.6,44 and 1.5mm35 did not confer a statistically
significant estimated nonmaturation risk in patients with
radiocephalic AVFs. The estimated pooled ERwas 8% (95%
CI, 0%-20%) and RR was 1.5 (95% CI, 0.9-2.5) times more
risk compared with patients with diameters above the cutoff
values. Moreover, two other included studies reported that
radial artery diameter was not significantly different be-
tween nonmaturation and maturation subgroups.34,36
Conversely, patients with minimum10,38 preoperative
cephalic vein diameters 2 mm10,37,38 or 1.6 mm44 had a
significant ER of 39% (95% CI, 27%-51%), an average risk
of 84%, and a significant RR of 1.9 (95% CI, 1.5-2.3).
However, three other articles reported a lack of significantdifferences in cephalic vein diameters between outcome
groups.33,34,36
Venous distensibility of the cephalic vein 0.5 mL/mm
Hgmeasured 1month before AVF creation conferred a risk
of 100%, an ER of 80% (95% CI, 62%-100%), and a RR of
6.0 (95% CI, 1.7-21) in a small series.34 Also, patients who
lacked change in radial artery peak systolic velocity during
and just after fist clenching had a risk of 48%, ER of 21%
(95% CI, 1%-41%), and a RR of 1.4 (95% CI, 1.0-1.9).36
Overall, a patient with preoperative imaging risk factors
was estimated to have 58% risk of nonmaturation, 24% ER
(95% CI, 15%-33%), and 1.7 times more risk (95% CI,
1.4-2.0) compared with a patient without risk factors.
Estimated sensitivity was 0.41 (95% CI, 0.35-0.48) and
specificity was 0.79 (95% CI, 0.74-0.83). Detailed results
are available in Table V.
The mean overall methodologic quality score for pre-
HRS studies was poor, at 51% (range, 44%-67%; Table II).
All studies lacked design adjustments to minimize observer
variability bias. Moreover, not a single study performed
validation of identified risk factors internally with statistical
resampling methods such as bootstrapping or externally in
a separate data set. Just one article used regression model-
ing to ensure identified risk factors were independent from
others. Otherwise, baseline characteristics were quite simi-
lar across studies (see Table III); therefore, the reported
contrasting results do not seem to be due to baseline
heterogeneity.
Efficacy of postoperative hemodynamic risk strati-
fication. Low flow within the venous side of the AVF was
identified as a significant risk factor for nonmaturation at
different cutoffs depending on the time at which it was
measured. For radiocephalic AVFs, cutoff values of 40
mL/min,39 measured immediately after creation, and 160
to 170 mL/min,40,42 10 minutes after creation, were iden-
tified. For brachiocephalic AVFs, the postoperative cutoff
was 280 mL/min at 10 minutes.40 In a mixed population
of brachiocephalic and radiocephalic AVFs measured 1
week after creation, the cutoff was set at 350 mL/min.11
All in all, venous flow below cutoffs conferred an average
estimated risk of 54%, an ER of 39% (95% CI, 28%-50%),
and 3.5 times (95% CI, 2.6-4.8) more risk compared with
patients with flows above the cutoff.41
Moreover, venous flow velocities 0.3 m/s at 1 day
postoperatively conferred a nonmaturation risk of 92%, an
ER of 85% (95%CI, 68%-100%), and a RR of 12.3 (95%CI,
4.1-37).44 On the arterial side, a high radial artery resistive
index [RI (peak systolic velocity end diastolic velocity)/
peak systolic velocity] 0.5 measured 2 weeks after AVF
creation conferred a risk of 67% vs a 7% risk when resistive
indices were0.5, and a RR of 10.2 (95% CI, 2.6-40).43
Robbin et al41 also found the risk of nonmaturation was
higher in patients with venous flow in the lower and upper
arm AVF 500 mL/min and AVF venous diameter 4
mm assessed somewhere within the first 4 months after
creation.41 A combination of both low flow and small
diameter gave the greatest nonmaturation risk, with an ER
of 62% and a RR of 13.3 (95% CI, 1.9-93.1).41 The clinical
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First author
Year
Sizea
Modb
Baseline
Prevf
%
Definitions
Treatment AVFs, No. Male Age, y RCc DMd VMe Nonmature Treatment success
Turmel-Rodrigues14 2001 69 NA 61% 63 91% 26%  . . . HD 300 mL/min
1 mon AC
1 HD 300
mL/min flow
Song15 2006 22 NA 68% 58 100% 68%  . . . Failed HD or C 1
mon AC
HD flow 300
mL/min
Falk16 2006 65 NA . . . . . . . . . . . .  42 US 500 or failed
C 3 mon AC
. . .
Shin17 2005 19 NA 63% 52 95% 53%  . . . Failed C 1 normal HD
Nassar18 2005 119 NA 65% 57 63% 58%  . . . Failed HD or C 8
wks AC
6 HD 4 wks
Clark19 2007 97 NA 65% 58 65% . . .  . . . Failed C 4-6 wks
AC
HD 500 mL/
min
Beathard20 2003 100 NA 70% 61 55% 49%  . . . Failed HD 3 mon
AC
HD flow 350
mL/min
Faiyaz22 2002 17 NA 82% 50 82% 12%  . . . . . . 1 HD
Asif23 2006 41 NA 72% 53 56% 32%  . . . . . . HD flow 350-
400 mL/min
McLafferty24,h 2007 30 NA 56% 60 1% 52%  18% Failed C every 6
wks HD
Clinical criteria
were met
Beathard21 1999 71 NA NR 57 68% 60%  . . . Failed C at 30 days HD 250 mL/
min for 90
days
Singh25 2007 95 NA 55% . . . 52% 63%  . . . Failed C 6 mon
AC
HD for 1 mon
Mean treatment 62 66% 57 66% 47%
Risk stratification
Preclinical
Lok9,g 2006 422 NA 68% 58 61% 28%  39% Inadequate
consistent HD
for 1 mon 6
mon AC
Pre-HRS
Korten33 2007 148 US 55% 65 100% 31%  11% Inadequate dialysis
access at 6 wks
post-AVF
creation
Parmar35 2007 21 US 71% 52 100% . . .  24% . . .
Van der Linden34 2006 17 US 82% 58 100% 6%  53% HD 250 mL/min
at 2 mon AC
Lockhart36 2004 89 US 64% 53 100% 52%  60% Flow 350 mL/
min in 1 of 6 HD
sessions
Tordoir37 2003 25 US 57% 67 100% 23%  40% HD 250 mL/min
6 wks AC
Brimle38 2002 106 US 64% 59 100% 46%  73% HD 300 mL/min
6 mon AC
Mendes10 2002 44 US 80% 56 100% . . .  50% Inadequate ongoing
HD 3 mon after
AC
Mean pre-op 64 68% 59 100% 32% 44%
Post-HRS
Robbin41 2002 52 US 57% 54 30% 61%  66% HD 350 mL/min
in 1 of the first 6
HD sessions
Chiang43 2001 49 US 45% 56 100% 43%  10% Thrombosis or
inadequate flow
4-6 wks AC
Kim11 2001 53 US 46% 53 89% 58%  19% . . .
Won42 2000 50 FP 56% 54 100% 61%  28% Unsuccessful HD
session 3 mon
after start HD
Johnson40 1998 227 FP 61% 53 43% 39%  23% . . .
Elfstrom39 1981 36 EMFP 68% 54 100% . . .  22% . . .
Mean post-op 78 55% 54 77% 52% 28%
ntil a
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because most AVFs should already have matured by 4
months.
On the whole, the estimated risk of a patient with risk
factors acquired with medical imaging techniques early
postoperatively was 65%, with an ER of 50% (95% CI,
42%-58%) and a RR of 4.3 (95% CI, 3.4-5.5). The esti-
Table III. Continued
First author
Year
Sizea
ModbTreatment AVFs, No. Male Age, y
Pre- and post-HRS
Wong44 1996 53 US 62% 59
. . ., Signifies data not reported; AC, after arteriovenous fistula creation; AV
and cannulation attempts); DM, diabetes mellitus; EMFP, electromagne
stratification; NA, not applicable; RC, radiocephalic; US, ultrasound; mon,
aSize: the number of AVFs for which risk factor values and outcome are rep
bMod: Imaging modality used to image hemodynamic risk factor(s).
cRC: Percentage of patients with radiocephalic AVF included in study.
dDM: Percentage of patients with diabetes mellitus included in study.
eVM: () indicates preoperative vascular mapping was performed, otherwis
fPrevalence: the prevalence of nonmaturation in percentages in the study po
gBaseline characteristics reported are from the derivation set, prevalence is f
hThis study followed up the AVF with clinical examinations every 6 weeks u
Table IV. Efficacy of early nonmaturation treatment
First author Year
AVF age, mon Detected lesions
Mean (range) AI JAn VO CV
Turmel-
Rodrigues14 2001 2.5 (1.0-6.5) 4 38 27 0
Song15 2006 2.7 (1.0-13) 0 18 4 0
Falk16 2006 2.0 (0.3-8.5) 16 32 33 2
Shin17 2005 1.5 (1.3-3.5) 1 13 5 1
Nassar18 2005 4.6 (2-24) 62 76 95 10
Clark19 2007 3.5 (0.7-14) 6 37 44 2
Beathard20 2003 4.7 42 15 20 9
Faiyaz22 2002 4.0 (1.7-7.5) . . . . . . . . . . . .
Asif23 2006 . . . . . . . . . . . . . . .
McLafferty24 2007 . . . . . . . . . . . . . . .
Beathard21 1999 5.0 (1-13.9) 0 17 4 0
Singh25 2007 . . . . . . . . . . . . . . .
Sum 131 246 232 24
Percentage, % 17 32 30 3
Weighted
average 3.2
. . ., Signifies that data were not clearly reported; AI, arterial inflow stenosis
central venous stenosis, located in the subclavian vein, innominate vein, or s
arteriovenous fistula; AVL, accessory vein ligation, including percutaneous
the initial 5 cm (2 inches) of the AVF starting just proximal of the anastomosi
balloon dilation, stenting, and endovascular thrombus aspiration techniques
created; Surg, nonrevision surgery, including all surgical procedures where
thrombectomy); VO, venous outflow stenosis, located 5 cm proximal of t
a1Y PP: 1-year primary patency rate.
b1Y SP: 1-year secondary patency rate.mated sensitivity was 0.58 (95% CI, 0.51-0.66) and speci-ficity was 0.88 (95% CI, 0.85-0.91). Table V provides
additional details.
The collection of post-HRS studies suffered from the
same methodologic flaws as described for the pre-HRS
groups. Accordingly, overall quality was poor, at 52%
(range, 22%-67%; Table II). Heterogeneity in baseline
characteristics, studied risk factors, and outcome defini-
ne
Prevf
%
Definitions
c DMd VMe Nonmature Treatment success
% 12%  28% HD flow 150
mL/min and/or
vein diam 3
mm 3 mon AC
riovenous fistula; C, clinical examination (includes palpation, auscultation,
w probes; FP, flow probes; HD, hemodialysis; HRS, hemodynamic risk
(s); VM, vascular mapping.
in a study.
.
ion.
he validation set.
dequate HD was possible or the AVF was classified as nonmatured.
Techniques used
Success
%
1Y PPa
%
1Y SPb
%V PTA AVE AVL Surg Rev
. . . . . . . . . . . . . . . 97 39 79
. . . . . . . . . . . . . . . 96 28 85
83 0 21 9 0 74 . . . . . .
19 0 0 0 0 74 61 82
. . . . . . . . . . . . . . . 83 62 95
85 1 3 0 0 88 34 72
110 34 12 0 0 92 68 . . .
. . . . . . . . . . . . . . . . 88 . . . . . .
. 69 0 0 0 0 93 46 94
. 23 0 2 1 12 84 . . . . . .
21 0 52 5 0 83 . . . 75
. . . . . . . . . . . . . . . 78 . . . . . .
410 35 90 15 12
73 6 16 3 2
86 51 76
ed in the radial or brachial artery up until the start of the anastomosis; CV,
r vena cava; AccV, accessory veins; AVE, accessory vein embolization; AVF,
n and ligation through incision; JAn, juxta-anastomosis stenosis, located in
, percutaneous transluminal angioplasty, including balloon dilation, cutting
revision surgery, including all techniques with which a new anastomosis was
riginal AVF was preserved (eg mainstream banding, superficialization, and
stomosis up until the distal edge of the subclavian vein.Baseli
RC
100
F, arte
tic flo
month
orted
e ()
pulat
rom tAcc
0
0
21
14
35
4
46
. .
. .
. .
21
44
141
18
, locat
uperio
ligatio
s; PTA
;Rev,
the o
he anations was considerable (Table III).
given
JOURNAL OF VASCULAR SURGERY
May 20091332 Voormolen et alDISCUSSION
To the best of our knowledge, we are the first to review
the literature with a systematic methodology on two clinically
Table V. Arteriovenous fistula nonmaturation risk due to
Risk factors First auth
Pre-HRS
Radial artery diameter, mm Korten 33 (20
Tordoir37 (20
Wong44 (199
Parmar35 (20
Estimate
Cephalic vein diameter, mm Mendes10 (20
Brimble38 (20
Tordoir37 (20
Wong44 (199
Estimate
Venous distensibility, mL/mm Hg Van der Lind
PSV during and after clenching, cm/s Lockhart36 (2
Overall estimate pre-HRS
Post-HRS
AVF venous flow, mL/min Elfstrom39 (1
Johnson40 (1
Won42 (2000
Kim11 (2001)
Robbin41 (20
Estimate
AVF venous flow velocity, m/s Wong44 (199
AVF venous diameter, mm Robbin41 (20
AVF venous diameter, mm  flow, mL/min Robbin41 (20
Radial artery resistive index Chiang43 (20
Overall estimate post-HRS
AC, After AVF creation; AVF, arteriovenous fistula; BC, before AVF creatio
Spec, specificity.
aTime: point in AVF lifetime at which it was imaged to acquire risk factor m
bCutoff: the cutoff value at which risk was stratified is reported under defini
() or () signifies multiple risk factors have been identified.
cNMR: nonmaturation risk as a percentage, for a nonmaturation definition
dER: (Absolute) excess risk when risk factor is present, with 95% confidenc
eRR: Relative risk when risk factor is present, with 95% confidence intervals
f#AVF: Number of AVFs what had values above cutoff () or below the cu
g?: In this study RR could not be calculated because nonmaturation did not
divided by zero.
hValues for cutoff points for radiocephalic/brachiocephalic venous flow areimportant issues.We used a broad search strategy tominimizethe risk of missing useful articles and subsequently excluded
the bulk, and were left with a body of relevant and valid
evidence. First, we show that radiologic and surgical interven-
odynamic risk factors
ar) Timea
Cutoffb
Definition #AVFf
. . . 2 

89
50
. . . 2 

20
5
. . . 1.6 

48
5
. . . 1.5 

10
11
. . . 2 

25
19
. . . 2 

82
24
. . . 2 

14
11
. . . 1.6 

50
3
(2006) 1 mon BC 0.5 

10
7
. . . 0 

56
33
Immediately AC 40 

29
7
10 min AC 170/280h 

196
30
10 min AC 160 

25
25
1 wk AC 350 

44
9
4 mon AC 500 

31
31
1 day AC 0.3 

40
13
4 mon AC 4 

27
26
4 mon 4  500 

20
15
2 wks AC 0.5 

3
46
confidence interval;HRS, hemodynamic risk stratification; Sens, sensitivity;
ements.
) means equal or higher than cutoff; () means lower than cut-off value,
h study, refer to Table III.
vals.
) per study.
in the not-at-risk subgroup (due to small sample) and the utilized formula
.hem
or (ye
07)
03)
6)
07)
02)
02)
03)
6)
en34
004)
981)
998)
)
02)
6)
02)
02)
01)
n; CI,
easur
tion; (
of eac
e inter
.
toff (
occurtions in AVFs with nonmaturation have a substantial success
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Volume 49, Number 5 Voormolen et al 1333rate. Secondary patency rates were high, and seem no worse
comparedwith “normal” cohorts includingAVFs that initially
matured.4,45 This might indicate that patients experiencing
AVF nonmaturation are eventually able to use their AVF for
long-term dialysis just as effectively as patients in whom the
AVF matured initially, although extra effort in terms of inter-
ventions would be required to achieve maturation and to
maintain patency.
Furthermore, treatment of AVFs experiencing non-
maturation appears to be safe: overall complication rates
were not high, and mostly minor complications occurred.
Most treatment studies lacked control groups, however, so
Table V. Continued
NMRc ERd 95% CI
10%
12%
2% (9% to 13%)
40%
40
0% (48% to 48%)
25%
100%
75% (63% to 87%)
0%
46%
46% (16% to 75%)
25% 8% (4% to 20%)
24%
84%
60% (37% to 84%)
66%
96%
30% (17% to 43%)
29%
55%
26% (12% to 64%)
26%
100%
74% (62% to 86%)
84% 39% (27% to 51%)
20%
100%
80% (62% to 100%)
27%
48%
21% (1% to 41%)
58% 24% (15% to 33%)
10%
71%
61% (26% to 96%)
17%
60%
43% (25% to 61%)
16%
40%
24% (0% to 48%)
11%
55%
44% (10% to 78%)
16%
57%
41% (16% to 66%)
54% 39% (28% to 50%)
7%
92%
85% (68% to 100%)
11%
56%
45% (22% to 66%)
5%
67%
62% (36% to 87%)
67%
7%
60% (6% to 100%)
65% 50% (42% to 58%)the effect of interventions in facilitating maturation is prob-ably overestimated because some AVFs might have ma-
tured without intervention.
Nevertheless, because early treatment of nonmatura-
tion appears effective, it has clinical value to identify those
patients who are at risk of nonmaturation and will likely
need treatment at an early stage. This allows organization
of treatment of these patients at about 4 weeks after AVF
creation, reducing additional maturation time past 6 weeks
and potential exposure to risks associated with alternative
vascular accesses. Therefore, we also aimed to identify the
most efficient method for nonmaturation risk stratification.
Second, we show that patients with hemodynamic risk
e 95% CI Sens Spec
.2 (0.4 to 3.1) 0.40 0.65
.0 (0.3 to 3.3) 0.20 0.80
.0 (2.5 to 6.5) 0.29 1.00
(?g to ?g) 1.00 0.63
.5 (0.9 to 2.5) 0.38 0.72
.5 (1.7 to 7.2) 0.73 0.86
.5 (1.2 to 1.7) 0.30 0.97
.9 (0.7 to 5.1) 0.60 0.67
.8 (2.4 to 6.1) 0.19 1.00
.9 (1.5 to 2.3) 0.38 0.91
.0 (1.7 to 21) 0.78 1.00
.4 (1.0 to 1.9) 0.50 0.80
.7 (1.4 to 2.0) 0.41 0.79
.9 (2.1 to 22) 0.63 0.93
.6 (2.3 to 5.5) 0.35 0.93
.5 (0.9 to 6.9) 0.71 0.58
.9 (1.8 to 13) 0.50 0.91
.5 (1.5 to 8.6) 0.71 0.74
.5 (2.6 to 4.8) 0.50 0.87
.3 (4.1 to 37) 0.80 0.97
.0 (1.3 to 3.1) 0.66 0.83
.3 (1.9 to 93) 0.91 0.79
.2 (2.6 to 40) 0.40 0.98
.3 (3.4 to 5.5) 0.58 0.88RR
1
1
4
?g
1
3
1
1
3
1
6
1
1
6
3
2
4
3
3
12
2
13
10factors acquired postoperatively have a significantly greater
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with clinical risk factors or preoperative hemodynamic risk
factors. Moreover, we show that post-HRS has higher
sensitivity and specificity compared with clinical risk estima-
tion and pre-HRSmethods. This is summarized graphically
in the Figure. However, note that the average sensitivity
was about 0.5 (with specificity of about 0.8) for all three
methods, which entails that many identified risk factors
were not better than chance in classifying an (future) AVF
as nonmaturing.
All in all, our results clearly indicate that early postop-
erative evaluation of hemodynamic risk factors is the most
effective modus operandi for nonmaturation risk stratifica-
tion. Yet, note that the superior results for post-HRS could
be due to publication bias or systematic differences in
baseline characteristics between compared groups.
However, additional circumstantial evidence authenti-
cating our observation is that hospital-related factors (eg,
vessel choice or surgical experience) importantly predict the
risk of nonmaturation.8 This indicates that the quality of
the AVF creation procedure and the resulting conduit itself
considerably influences the risk of nonmaturation. Appar-
ently, AVF nonmaturation is the result of interplay between
a patient’s vascular remodeling capacity and hemodynamic
forces within the AVF.46 Preoperative risk stratification can
only assess risk of nonmaturation due to “bad” remodeling
capacity. Conversely, post-HRS, incorporating the hemo-
dynamic profile of the AVF into the equation, offers a more
comprehensive risk prediction. Therefore, although ideally
one would like to identify at-risk patients preoperatively,
Fig. Graphic display of summarymeasures of the excess n
risk (value reported is divided by 10) with 95% confidenc
a preoperative clinical prediction rule (pre-Clin) and p
postoperative hemodynamic risk stratification (post-HRS
excess risk and relative risk) and has a better discriminativ
clinical prediction rule and pre-HRS.risk stratification at the early postoperative stage appears tobe more predictive and allows for early intervention strate-
gies that positively influence AVF maturation in an expedi-
tious fashion.
A limitation of the reviewed post-HRS studies was low
quality and heterogeneity in studied risk factors, cutoff values,
and times at which factors were acquired, in combinationwith
small sample sizes. This limits the utility of this review, because
we cannot use the current evidence to advocate the use of a
particular post-HRS protocol in the clinic.
We clearly show, however, that post-HRS is relevant
and has potential. Moreover, the results summarized here
allow generation of educated hypotheses for future re-
search. For example, it appears that within a time window
of 2 weeks after AVF creation, functional AVF parameters
such as flow and distensibility are able to stratify patients
into an at-risk category of 60% nonmaturation risk and a
not at-risk category of10% nonmaturation risk. Although
presently these hemodynamic criteria entail a high unnec-
essary intervention rate of 40% in the at-risk group, we hope
that further investigation will make it possible to more
appropriately identify patients at risk to such extent that
early treatment of all patients in the at-risk category be-
comes acceptable.
The overall results of this review illustrate that post-
HRS in combination with early treatment might be a viable
means to address nonmaturation and its associated prob-
lems. Many practical details nevertheless remain unre-
solved. Therefore, we strongly wish to instigate novel in-
vestigations and stress the need for better-quality research
aturation risk (reported in %) and relative nonmaturation
rvals, and sensitivity (%) and specificity (%) measures for
erative hemodynamic risk stratification (pre-HRS) and
thods. On average, post-HRS stratifies risk best (higher
ity (higher sensitivity and specificity) compared with theonm
e inte
reop
) me
e abilto forge this idea into a clinically useful instrument.
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Volume 49, Number 5 Voormolen et al 1335CONCLUSIONS
This systematic review demonstrates that AVFs experi-
encing nonmaturation can be treated early, safely, and
effectively. Furthermore, this review shows that hemody-
namic risk factors measured postoperatively stratify risk of
nonmaturation most effectively. As a consequence, acquir-
ing these risk factors early in the AVF maturation period to
select patients in need of early treatment might facilitate
minimization of additional maturation time. However,
heterogeneity and poor quality of the gathered evidence
prohibits the introduction of such patient management
practice into the clinical setting at the moment. Addi-
tional research is needed to develop it into a valuable
clinical tool.
AUTHOR CONTRIBUTIONS
Conception and design: EV, AJ, LB
Analysis and interpretation: EV, AJ, PB, WM
Data collection: EV, AJ, LB
Writing the article: EV, PB, WM
Critical revision of the article: EV, PB, AJ, FM
Final approval of the article: EV, AJ, LB, FM, WM, PB
Statistical analysis: EV
Obtained funding: Not applicable
Overall responsibility: EV, AJ, LB, FM, WM, PB
REFERENCES
1. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al.
EBPG on Vascular Access. Nephrol Dial Transplant 2007;22(suppl
2):ii88-117.
2. National Kidney Foundation. Clinical practice guidelines for vascular
access: Update 2006. Am J Kidney Dis 2006;48(suppl 1):S176-247.
3. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E,
Gillespie B, et al. Vascular access use in Europe and the United States:
results from the DOPPS. Kidney Int 2002;61:305-16.
4. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis
patients: problems and solutions. Kidney Int 2002;62:1109-24.
5. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost
analysis of ongoing care of patients with end-stage renal disease: the
impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;
40:611-22.
6. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access
and all-cause mortality: a propensity score analysis. J Am Soc Nephrol
2004;15:477-86.
7. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW,
Pisoni RL, et al. Predictors of early mortality among incident US
hemodialysis patients in the Dialysis Outcomes and Practice Patterns
Study (DOPPS). Clin J Am Soc Nephrol 2007;2:89-99.
8. Huijbregts HJ, Bots ML, Moll FL, Blankestijn PJ. Hospital specific
aspects predominantly determine primary failure of hemodialysis arte-
riovenous fistulas. J Vasc Surg 2007;45:962-7.
9. Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D. Risk
equation determining unsuccessful cannulation events and failure to
maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc
Nephrol 2006;17:3204-12.
10. Mendes RR, Farber MA, Marston WA, Dinwiddie LC, Keagy BA,
Burnham SJ. Prediction of wrist arteriovenous fistula maturation with
preoperative vein mapping with ultrasonography. J Vasc Surg 2002;
36:460-3.
11. Kim YO, Yang CW, Yoon SA, Chun KA, Kim NI, Park JS, et al. Access
blood flow as a predictor of early failures of native arteriovenous fistulas
in hemodialysis patients. Am J Nephrol 2001;21:221-5.12. Dutch Cochrane Collaboration. Dutch Cochrane Collaboration Co-
hort and RCT Checklists. Dutch Cochrane Collaboration 2008.
http://www.cochrane.nl/index.html.
13. Vandenbroucke JP, Hofman A. Grondslagen der Epidemiologie. 6th
ed. Maarssen: Elsevier; 1999.
14. Turmel-Rodrigues L,MoutonA, Birmele B, BillauxL, AmmarN,Grezard
O, et al. Salvage of immature forearm fistulas for haemodialysis by inter-
ventional radiology. Nephrol Dial Transplant 2001;16:2365-71.
15. Song HH, Won YD, Kim YO, Yoon SA. Salvaging and maintaining
non-maturing Brescia-Cimino haemodialysis fistulae by percutaneous
intervention. Clin Radiol 2006;61:404-9.
16. Falk A. Maintenance and salvage of arteriovenous fistulas. J Vasc Interv
Radiol 2006;17:807-13.
17. Shin SW, Do YS, Choo SW, Lieu WC, Choo IW. Salvage of immature
arteriovenous fistulas with percutaneous transluminal angioplasty. Car-
diovasc Intervent Radiol 2005;28:434-8.
18. Nassar GM, Nguyen B, Rhee E, Achkar K. Endovascular treatment of
the “failing to mature” arteriovenous fistula. Clin J Am Soc Nephrol
2006;1:275-80.
19. Clark TW, Cohen RA, Kwak A, Markmann JF, Stavropoulos SW, Patel
AA, et al. Salvage of nonmaturing native fistulas by using angioplasty.
Radiology 2007;242:286-92.
20. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of
early fistula failure. Kidney Int 2003;64:1487-94.
21. Beathard GA, Settle SM, Shields MW. Salvage of the nonfunctioning
arteriovenous fistula. Am J Kidney Dis 1999;33:910-6.
22. Faiyaz R, Abreo K, Zaman F, Pervez A, Zibari G, Work J. Salvage of
poorly developed arteriovenous fistulae with percutaneous ligation of
accessory veins. Am J Kidney Dis 2002;39:824-7.
23. Asif A, Lenz O, Merrill D, Cherla G, Cipleu CD, Ellis R, et al.
Percutaneous management of perianastomotic stenosis in arteriovenous
fistulae: results of a prospective study. Kidney Int 2006;69:1904-9.
24. McLafferty RB, Pryor RW 3rd, Johnson CM, Ramsey DE, Hodgson
KJ. Outcome of a comprehensive follow-up program to enhance mat-
uration of autogenous arteriovenous hemodialysis access. J Vasc Surg
2007;45:981-5.
25. Singh P, Robbin ML, Lockhart ME, Allon M. Clinically immature
arteriovenous hemodialysis fistulas: effect of US on salvage. Radiology
2007;246:299-305.
26. Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K.
Predictors of successful arteriovenous fistula maturation. Am J Kidney
Dis 2003;42:1000-12.
27. Lin SL, Huang CH, Chen HS, HsuWA, Yen CJ, Yen TS. Effects of age
and diabetes on blood flow rate and primary outcome of newly created
hemodialysis arteriovenous fistulas. Am J Nephrol 1998;18:96-100.
28. Miller CD, Robbin ML, Allon M. Gender differences in outcomes of
arteriovenous fistulas in hemodialysis patients. Kidney Int 2003;63:
346-52.
29. Murphy GJ, Nicholson ML. Autogeneous elbow fistulas: The effect of
diabetes mellitus on maturation, patency, and complication rates. Eur J
Vasc Endovasc Surg 2002;23:452-7.
30. Golledge J, Smith CJ, Emery J, Farrington K, Thompson HH. Out-
come of primary radiocephalic fistula for haemodialysis. Br J Surg
1999;86:211-6.
31. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT,
et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis
patients. Kidney Int 1999;56:275-80.
32. Ernandez T, Saudan P, Berney T, Merminod T, Bednarkiewicz M,
Martin PY. Risk factors for early failure of native arteriovenous fistulas.
Nephron Clin Pract 2005;101:c39-44.
33. Korten E, Toonder IM, Schrama YC, Hop WC, van der Ham AC,
Wittens CH. Dialysis fistulae patency and preoperative diameter ultra-
sound measurements. Eur J Vasc Endovasc Surg 2007;33:467-71.
34. van der Linden J, Lameris TW, van den Meiracker AH, de Smet AAEA,
Blankestijn PJ, van den Dorpel MA. Forearm venous distensibility
predicts successful arteriovenous fistula. Am J Kidney Dis 2006;47:
1013-9.
35. Parmar J, Aslam M, Standfield N. Pre-operative radial arterial diameter
predicts early failure of arteriovenous fistula (AVF) for haemodialysis.
Eur J Vasc Endovasc Surg 2007;33:113-5.
JOURNAL OF VASCULAR SURGERY
May 20091336 Voormolen et al36. Lockhart ME, Robbin ML, Allon M. Preoperative sonographic radial
artery evaluation and correlation with subsequent radiocephalic fistula
outcome. J Ultrasound Med 2004;23:161-8.
37. Tordoir JH, Rooyens P, Dammers R, van der Sande FM, de HM, Yo TI.
Prospective evaluation of failure modes in autogenous radiocephalic wrist
access for haemodialysis. Nephrol Dial Transplant 2003;18:378-83.
38. Brimble KS, Rabbat C, Treleaven DJ, Ingram AJ. Utility of ultrasono-
graphic venous assessment prior to forearm arteriovenous fistula cre-
ation. Clin Nephrol 2002;58:122-7.
39. Elfstrom J, Thomsen M. The prognostic value of blood-flow measure-
ments during construction of arteriovenous fistulae. Scand J Urol
Nephrol 1981;15:323-6.
40. Johnson CP, Zhu YR, Matt C, Pelz C, Roza AM, Adams MB. Prog-
nostic value of intraoperative blood flow measurements in vascular
access surgery. Surgery 1998;124:729-37.
41. Robbin ML, Chamberlain NE, Lockhart ME, Gallichio MH, Young
CJ, Deierhoi MH, et al. Hemodialysis arteriovenous fistula maturity:
US evaluation. Radiology 2002;225:59-64.42. Won T, Jang JW, Lee S, Han JJ, Park YS, Ahn JH. Effects of intraop-
erative blood flow on the early patency of radiocephalic fistulas. Ann
Vasc Surg 2000;14:468-72.
43. Chiang WC, Lin SL, Tsai TJ, Hsieh BS. High resistive index of the
radial artery is related to early primary radiocephalic hemodialysis fistula
failure. Clin Nephrol 2001;56:236-40.
44. Wong V, Ward R, Taylor J, Selvakumar S, How TV, Bakran A. Factors
associated with early failure of arteriovenous fistulae for haemodialysis
access. Eur J Vasc Endovasc Surg 1996;12:207-13.
45. Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL,
Blankestijn PJ, et al. Hemodialysis Arteriovenous fistula patency revis-
ited: results of a prospective, multicenter initiative. Clin J Am Soc
Nephrol 2008;3:714-9.
46. Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P. Biology of
arteriovenous fistula failure. J Nephrol 2007;20:150-63.Submitted Aug 17, 2008; accepted Nov 16, 2008.
